Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 11, 2026

Stock market today: S&P 500 and Nasdaq rise, Dow slips amid fresh inflation data, continued Iran fallout

View original at finance.yahoo.com
Stock market today: S&P 500 and Nasdaq rise, Dow slips amid fresh inflation data, continued Iran fallout US stocks split at the opening bell on Wednesday as investors eyed attacks on shipping in the Iran war and assessed the latest inflation report, which came in line with expectations…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The February CPI report covers the period before the war with Iran broke out, which has raised gas prices and fueled concerns of higher utility bills

    60% confidence

  • The CPI report covers the period before the war with Iran broke out, which has raised gas prices and fueled concerns of higher utility bills

    60% confidence

  • Higher memory chip prices weighed on HPE's quarter

    60% confidence

  • Perhaps more important than the February data is the evolving risk space for inflation. A longer Iran conflict would put upward pressure on headline, core inflation and inflation expectations in the months ahead.

    60% confidence

  • Perhaps more important than the February data is the evolving risk space for inflation. A longer conflict would put upward pressure on headline, core inflation and inflation expectations in the months ahead.

    60% confidence

  • The pace of growth improvement in 2026 will be more moderate than the trajectory we were building toward. The headwinds in organic, owned, and enterprise channels are addressable, and we have clear action plans against each, but the fixes will take time to compound.

    60% confidence

  • Starboard supports CarMax's incoming CEO Keith Barr but is looking to accelerate the used-car dealer's turnaround plans

    60% confidence

  • The pace of growth improvement in 2026 will be more moderate than the trajectory we were building toward. The headwinds in organic, owned, and enterprise channels are addressable with clear action plans, but the fixes will take time to compound.

    60% confidence

  • Starboard supports CarMax's incoming CEO Keith Barr but is looking to accelerate the used-car dealer's turnaround plans

    60% confidence

  • Higher memory chip prices weighed on HPE's quarter

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com